Shard Capital Research Report
News Release | NEWSROOM
WideCells presents an early-stage investment opportunity linked to the burgeoning field of stem cell medicine. The company combines a range of stem cell cryopreservation services, including umbilical cord blood and tissue, dental pulp and adipose tissue with a complementary insurance product designed to cover the costs of stem cell therapies. The IPO provides a cash injection to enable WideCells to execute a business plan that should have growing and recurrent revenue with attractive economics over time. The current valuation could provide an attractive entry point for this new business.
Read the full research report here: https://www.shardcapitalstockbrokers.com/news/904-shard-capital-initiate-coverage-widecells-plc-maiden-research-report#.V7GEme0H_HE.twitter